Nanolek

Nanolek is a prominent, revenue-generating Russian biopharma player with a dual focus on vaccines and specialty therapeutics. The company has established a strong commercial footprint, ranking among the top 10 suppliers in Russia's state procurement market, and is actively advancing its R&D capabilities, notably in novel vaccines and treatments for orphan diseases. Its strategic priorities include import substitution, expanding its pediatric vaccine portfolio (including a first Russian HPV vaccine), and leveraging its integrated platform from research to GMP manufacturing.

Integrated vaccine and biopharmaceutical development platform, from molecule design and pilot-scale production in its Scientific and Practical Center to full-scale GMP manufacturing at its plant.

Operates in a competitive Russian market with other domestic champions vying for state contracts under the import substitution policy. Faces competition from established multinational companies in areas where imports are still feasible, and from other Russian biotechs developing similar localized vaccines and biosimilars.